GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 6 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphomaLeukemia · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE268034_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1114078 and SRA study SRP508995. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 6 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8284502 SUDHL4_LacZ_RGFP0_1 SUDHL4_LacZ_RGFP0
- GSM8284503 SUDHL4_LacZ_RGFP0_2 SUDHL4_LacZ_RGFP0
- GSM8284504 SUDHL4_LacZ_RGFP5_1 SUDHL4_LacZ_RGFP5
- GSM8284505 SUDHL4_LacZ_RGFP5_2 SUDHL4_LacZ_RGFP5
- GSM8284506 SUDHL4_GNASKO2_RGFP0_1 SUDHL4_GNASKO2_RGFP0
- GSM8284507 SUDHL4_GNASKO2_RGFP0_2 SUDHL4_GNASKO2_RGFP0
- GSM8284508 SUDHL4_GNASKO2_RGFP5_1 SUDHL4_GNASKO2_RGFP5
- GSM8284509 SUDHL4_GNASKO2_RGFP5_2 SUDHL4_GNASKO2_RGFP5
- GSM8284510 SUDHL4_GNASKO3_RGFP0_1 SUDHL4_GNASKO3_RGFP0
- GSM8284511 SUDHL4_GNASKO3_RGFP0_2 SUDHL4_GNASKO3_RGFP0
- GSM8284512 SUDHL4_GNASKO3_RGFP5_1 SUDHL4_GNASKO3_RGFP5
- GSM8284513 SUDHL4_GNASKO3_RGFP5_2 SUDHL4_GNASKO3_RGFP5
- GSE302692 Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [MD901_RNAseq_Day5] 12 samples shares hdac3, lymphoma
- GSE316603 HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway 12 samples shares hdac3, inhibition
- GSE310305 Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [OCI_ly7_RNAseq_Day5] 12 samples shares hdac3, lymphoma
- GSE303134 Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [MAC-seq] 1 samples shares hdac3, lymphoma
- GSE302670 Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [ChIP-seq] 13 samples shares hdac3, lymphoma
- GSE272475 SUMOylation inhibition potentiates CAR T activity against Multiple Myeloma 20 samples shares potentiates, inhibition
- GSE272300 SUMOylation inhibition potentiates CAR T activity against multiple myeloma (RNA-Seq) 16 samples shares potentiates, inhibition
- GSE233589 BET bromodomain inhibition potentiates ocular melanoma therapy by inducing cell cycle arrest 8 samples shares potentiates, inhibition
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.